Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | QPCT | Q16769 | 2/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223641 | 0.95 | TBXAS1 (0.64) | TBXAS1CYP19A1QPCTPRKCI | |
| SCHEMBL28191014 | 0.93 | TBXAS1 (0.67) | TBXAS1CYP19A1QPCT | |
| SCHEMBL2232319 | 0.93 | TBXAS1 (0.67) | TBXAS1CYP19A1QPCT | |
| Water SCHEMBL28581002 | 0.93 | TBXAS1 (0.62) | TBXAS1CYP19A1QPCTPRKCI | |
| Hydrochloric Acid SCHEMBL14801508 | 0.93 | TBXAS1 (0.62) | TBXAS1CYP19A1QPCTPRKCI | |
| SCHEMBL19772386 | 0.93 | TBXAS1 (0.66) | TBXAS1CYP19A1QPCTPRKCIKDM4E | |
| Hydrochloric Acid SCHEMBL14802021 | 0.92 | TBXAS1 (0.65) | TBXAS1CYP19A1QPCT | |
| SCHEMBL28694303 | 0.89 | TBXAS1 (0.55) | TBXAS1CYP19A1QPCTPRKCIKDM4E | |
| SCHEMBL22313371 | 0.87 | TBXAS1 (0.77) | TBXAS1 | |
| SCHEMBL11565567 | 0.86 | TBXAS1 (0.50) | TBXAS1CYP19A1QPCTPRKCILMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322575-A1 | LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY | NUTCRACKER THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322575-A1 | LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY | PHOSPHO1, PLIN3, CETP | TBXAS1 2552/4885CYP19A1 4701/4885QPCT 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.